Nevro (NVRO) Set to Announce Quarterly Earnings on Monday

Nevro (NYSE:NVRO) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, November 11th. Analysts expect the company to announce earnings of ($0.82) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Nevro Price Performance

NYSE NVRO opened at $5.08 on Friday. The firm has a market cap of $189.40 million, a P/E ratio of -2.38 and a beta of 0.93. The stock’s 50-day moving average is $5.25 and its two-hundred day moving average is $7.56. Nevro has a fifty-two week low of $4.38 and a fifty-two week high of $22.64. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.77 and a quick ratio of 3.53.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Royal Bank of Canada dropped their price objective on shares of Nevro from $16.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday, August 7th. Morgan Stanley reduced their price target on shares of Nevro from $14.00 to $9.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. JMP Securities downgraded shares of Nevro from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 7th. Robert W. Baird decreased their target price on shares of Nevro from $11.00 to $8.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. downgraded shares of Nevro from a “neutral” rating to an “underweight” rating in a research report on Wednesday, August 7th. Three analysts have rated the stock with a sell rating and twelve have issued a hold rating to the company’s stock. According to data from MarketBeat, Nevro has a consensus rating of “Hold” and a consensus target price of $9.80.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.